ICON PLC (ICLR) stock

ICLRNasdaqServices-Commercial Physical & Biological Research

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 20-F on May 27, 2026Score 7/30

$194.65−5.86 (-2.92%)

Close on Nov 13, 2026Market cap $14.90BP/E 33.5Yield –

ICON r&d expenses

Research and development expenses are spending on new products and technology.

ICON has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ICLR.

Revenue growth0.4% · median 8.8%

Gross margin23.4% · median 33.1%

Operating margin8.7% · median 10.4%

Net margin5.4% · median 6.7%

Advertisement
300 × 250

See a number that looks wrong?